Elbion and 4AZA merge
Leuven – The German Degussa spin-off Elbion AG has acquired the Belgian 4AZA Bioscience NV. The new company will have two clinical compounds including Elbion’s AWD-12-281, a small molecule phosphodiesterase-4 inhibitor in phase II partnered with GSK and Elbion’s ELB245. The ion channel modulator is tested in phase II to treat overactive bladder. 4AZA adds a preclinical HCV programme, which is partnered with Gilead Sciences. The current Elbion CEO will be head of the combined group, which is called Elbion NV with headquarters in Leuven, Belgium.